Related Papers
International Journal of Gynecological Cancer
Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors
2009 •
Julia Bar
Expression of P53 Protein in Neoplastic and Non Neoplastic Ovarian Lesions
2013 •
Haider Sabah Kadhim
Gynecologic Oncology
Distinct subtypes of serous ovarian carcinoma identified by p53 determination☆ ☆☆ ☆☆ Supplementary data associated with this article can be found at doi: 10.1016/S0090-8258(03)00608-5
2003 •
Johan Lundin
IOSR Journals
Role of Expression of P53 in Differentiating Benign, Borderline and Malignant Surface Epithelial Ovariantumors
2019 •
IOSR Journals
Introduction: Ovarian carcinoma is 6th most common cancer among the women worldwide. Surface epithelial ovarian tumors accounts for two third of all ovarian neoplasms and their malignant form represent about 90% of ovarian cancers. One of the most studied prognostic marker in ovarian cancer so far is overexpression of p53. Intranuclear accumulation of p53 has been detected in as many as 69% ovarian carcinomas by immunohistochemical studies. Method and material: All the cases of surface epithelial ovarian tumors diagnosed during study period classified according to WHO classification. Immunohistochemical analysis was done with p53 marker. Results: A total of 156 cases were studied, out of which benign tumors were the most common 117 cases (75%), followed by malignant tumors 33 cases (21%) and 6 cases (4%) of borderline malignancy. P53 immunostaining on 6 borderline surface epithelial ovarian ,out of 4 borderline serous cystadenomas 75 % were p53 positive and both borderline mucinous cystadenomas were p53 positive. P53 immunostaining on 33 malignant surface epithelial ovarian tumors, 78.2%serous cystadenocarcinoma were p53 positive and 71.5% mucinouscystadenocarcinoma were p53 positive. 100% Endometrioid and Adenosarcoma of ovary were p53 positive. Conclusion: P53 expression was high in malignant lesions compared to benign and borderline lesions, this emphasize their importance in the pathogenesis of surface epithelial ovarian cancer and suggest a relevant role in the progression to the invasive phenotype. In the present study correlation of p53 expression with histological type, stage and grade of tumor was found statistically insignificant. The limitations of study were restricted number of samples and using only one marker.
Mediscope
Correlation of p53 Expression with Grade and Stage of Ovarian Surface Epithelial Cancer
Neaz Nowsher
Introduction: Advanced ovarian cancer is characterized by a poor prognosis and the development of resistance to chemotherapy. In the absence of definite etiologic factors and effective tools for screening, the only possible means of improving survival would be to develop effective targeted therapy. Expression of p53 in ovarian cancer may serve as a promising therapeutic strategy to treat, prevent visceral metastasis and relapse. Objective: The study was carried out to find out the correlation of p53 expression with the grade and stage of ovarian cancers. Methods: The study had 45 cases. These cases were previously reported as ovarian surface epithelial cancers. Grading was done in all cases. Pathological staging of tumour (pT) was done in 30 cases and pathological staging of lymph node metastasis (pN) was done in 10 cases. Distant metastasis was present in only 1 case. Result: p53 immunostaining was found positively correlated & associated with the grade & stage of ovarian surface e...
IP innovative publication pvt ltd
Immunohistochemical expression of p53 in serous carcinoma of ovary and its correlation with clinicopathological parameters
2020 •
IP Innovative Publication Pvt. Ltd., P. Kumar
Introduction: Ovarian carcinoma is one of the most prevalent causes of mortality associated with carcinoma in women. More than 90% of ovarian cancer originates from epithelial cells. Multiple oncogene and tumour suppressor genes are involved in ovarian carcinogenesis among which p53 gene is found to be most frequently mutated. Aim: To study the immunohistochemical expression of p53 in serous carcinoma of ovary and its correlation with clinico pathological parameters. Materials and Methods: This study was carried over 18 histopathologically confirmed cases of serous carcinoma of ovary in VSSIMSR, Burla through a period of 1 year. Analysis of p53 expression was done immunohistochemically. Results: Out of total 18 cases of serous carcinoma, 14 cases were high grade and 4 cases were low grade. While 78.57% (11) cases of HGSOC were diagnosed in advanced stages (FIGO Stage III and IV); advanced stage (FIGO Stage III) case reported for LGSOC was limited to just 25% (1). Further while only 50% cases of LGSOC were positive for p53 immunostaining, it was 100% in case of HGSOC. Mean value of preoperative CA-125 was high in HGSOC as compared to LGSOC. Conclusion: The significant difference in p53 expression between HGSOC and LGSOC, indicates an altogether different pathogenesis of these tumours. The aggressive nature of this tumour is also suggested by the higher preoperative CA-125 values in case of HGSOC and diagnosis at a time when the tumour has already advanced.
Clinical Biochemistry
Fragment analysis of the p53 gene in ovarian tumors
1998 •
Katerina Angelopoulou
Indonesian Journal of Obstetrics …
Prognostic value of p53 gene in ovarian cancer
2011 •
Syahrul Rauf
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
The study of p53 and p16 immunoexpression in serous borderline and malignant ovarian tumors
2012 •
Marius Cristian Marinas
The study assessed p53 and p16 immunoexpression in 20 cases of ovarian serous carcinomas and four cases of serous borderline tumors, the results being statistically analyzed in relation to clinicopathological data of the cases. The p53 immunoreaction was observed in 85% of cases, the medium percentage of positivity being 15% for borderline tumors, 45% for low-grade carcinomas and 60% for high-grade carcinomas. The p16 immunoreaction was observed in 75% of cases, the medium percentage of positivity being 30% for borderline tumors, 25% for low-grade carcinomas and 62% for high-grade carcinomas. The p53 and p16 reaction was also identified at the tubal epithelium in cases of invasive carcinomas. Statistical analysis indicated significant differences in p53 expression depending on tumor type and for p53 and p16 expression compared to the degree of tumor differentiation. The study indicated a diffuse immunostain for p53 and p16 in high-grade serous ovarian carcinomas. The presence of &qu...
British journal of cancer
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study
1997 •
Silvia Pellegrini, Vittoria Carnicelli
Chemotherapeutic management of ovarian cancers is a difficult task as these neoplasms show significant differences in chemosensitivity, even if they share identical clinicopathological features. The present study was undertaken to investigate the prognostic and predictive role of p53 alterations in ovarian cancer. To this end, using different technical approaches, i.e. genetic and immunohistochemical analyses, we analysed a series of 68 ovarian neoplasms including 15 low malignant potential (LMP) tumours and 53 invasive carcinomas. We never observed p53 abnormalities in LMP tumours. p53 alterations were present only in invasive ovarian carcinomas, and they were detected much more frequently in tumours characterized by high histological grade (P = 0.01) and advanced-stage disease (P = 0.006 and P = 0.05 for gene mutations and protein expression respectively). For 33 patients with invasive ovarian cancer, information was available concerning response to cisplatin-based chemotherapy. A...
